|
|
735 Galveston Dr
Redwood City, CA 94063 USA
phone:+1 650 385 2999
fax:+1 650 363 8929
|
|
| Symbol |
AAH |
| Exchange |
ASX |
| Founded |
0 |
| Employees |
|
|
|
| www.arana.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development of treatment of inflammatory diseases such as rheumatoid arthritis and cancer. |
|
| Management |
| Steffen Nock PhD, Acting CEO; President, US Operations; Niall Henderson BAcc, CA, ACA, AICD, Chief Financial Officer and Company Secretary; Phil Jennings BSc, BVSc (Hons), PhD, FTSE, Chief Scientific Officer; Steffen Nock PhD, Acting CEO, President, US Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| therapeutics, autoimmune, inflammatory, astrazeneca, rheumatoid |
|
|
|
| Description |
|
Arana Therapeutics, a global company working in the fast-growing antibody therapeutics sector created by the merger of Peptech Limited and EvoGenix Limited. Arana's vision is to improve patients' lives by developing new generation products and platforms for the treatment of inflammatory diseases such as rheumatoid arthritis and cancer. The business is focused on expanding and accelerating the development of its internal clinical pipeline, leveraging its technology platforms to in-license new drug candidates and seeking commercial partners at the optimum stage of drug development. Arana Therapeutics trades on the Australian Stock Exchange as AAH and the AIM exchange in the UK under AAHx. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
